Discussion {#onco12812-sec-0006}
==========

Single‐agent gemcitabine has modest activity in patients with advanced adenocarcinoma of the pancreas. Gemcitabine was shown to be superior to 5‐fluorouracil with an improvement in a composite endpoint of pain, performance status, and weight (clinical benefit response) and a modest prolongation of overall survival \[[1](#onco12812-bib-0001){ref-type="ref"}\]. Multiple trials have compared gemcitabine alone with combinations of gemcitabine and both cytotoxic and molecularly targeted drugs and failed to show improvement over gemcitabine alone. A large trial conducted by the National Cancer Institute of Canada compared gemcitabine with and without erlotinib in patients with locally advanced or metastatic pancreatic cancer. The overall survival (OS) in the combination arm was statistically superior to the gemcitabine alone arm (6.2 months vs. 5.9 months), but the increase in the overall survival was of questionable clinical importance \[[2](#onco12812-bib-0002){ref-type="ref"}\]. Another large trial compared gemcitabine monotherapy with the combination of gemcitabine and cetuximab \[[3](#onco12812-bib-0003){ref-type="ref"}\]. Although the combination resulted in a slightly longer overall survival (5.9 months vs. 6.3 months), the difference was not statistically different. Given evidence from preclinical and translational studies suggesting synergistic efficacy of different classes of anti‐EGFR agents, this trial was performed \[[4](#onco12812-bib-0004){ref-type="ref"}\], \[[5](#onco12812-bib-0005){ref-type="ref"}\].

Designed as a randomized phase II trial, evaluating the efficacy of a combined EGFR inhibition using erlotinib and panitumumab in conjunction with gemcitabine with gemcitabine plus erlotinib as a reference arm, 92 patients were enrolled, 46 on each arm. The patient characteristics were balanced between the arms. The primary endpoint was OS, with progression‐free survival (PFS), radiographic response rate, and toxicity as secondary endpoints. The trial was designed to detect with 80% power a difference in the primary outcome between arms using a one‐sided log‐rank test with an α of .20. A *p* value less than .20 was therefore considered significant for OS.

The median OS was longer in the combined EGFR inhibition plus gemcitabine arm (Arm B) compared with gemcitabine with erlotinib (Arm A)---8.3 months versus 4.2 months---and met statistical significance (hazard ratio, 0.817; 95% CI, 0.530--1.260; *p* = .1792) (Fig. [1](#onco12812-fig-0001){ref-type="fig"}). A nonsignificant difference in the PFS was seen, favoring Arm B (median: 3.6 months in Arm B and 2.0 months in Arm A; hazard ratio 0.843; 95% CI, 0.555--1.280; *p* = .4190) (Fig. [2](#onco12812-fig-0002){ref-type="fig"}). A partial response was seen in 8.7% of patients on Arm A and 6.5% on Arm B (*p* = .9999). No patients had a complete response. Grade 3 and higher nonhematologic toxicities were more common in patients receiving combined EGFR inhibition therapy (82.6% vs. 52.2%; *p* = .0018).

![Overall survival by treatment arm.\
Abbreviations: CI, confidence interval; EGFR, epidermal growth factor receptor; Gem, gemcitabine.](onco12812-fig-0001){#onco12812-fig-0001}

Trial Information {#onco12812-sec-0007}
=================

DiseasePancreatic cancerStage of Disease/TreatmentMetastatic/advancedPrior TherapyNoneType of Study ‐ 1Phase IIType of Study ‐ 2RandomizedPrimary EndpointOverall survivalSecondary EndpointProgression‐free survivalSecondary EndpointOverall response rateSecondary EndpointToxicityAdditional Details of Endpoints or Study DesignThe trial was opened on December 30, 2009 and was closed to accrual on August 13, 2010. Trial information and patient characteristics are summarized in Table [1](#onco12812-tbl-0001){ref-type="table"}.Investigator\'s AnalysisLevel of activity did not meet planned endpoint.

Drug Information (Control -- Arm A) {#onco12812-sec-0008}
===================================

Drug 1  **Generic/Working Name**Gemcitabine **Drug Class**Antimetabolite **Dose**1,000 milligrams (mg) per squared meter (m^2^) **Route**IV **Schedule of Administration**On days 1, 8, and 15 of a 28‐day cycleDrug 2  **Generic/Working Name**Erlotinib **Drug Class**EGFR **Dose**100 milligrams (mg) **Route**Oral (p.o.) **Schedule of Administration**Daily

Drug Information (Experimental -- Arm B) {#onco12812-sec-0009}
========================================

Drug 1  **Generic/Working Name**Gemcitabine **Drug Class**Antimetabolite **Dose**1,000 milligrams (mg) per squared meter (m^2^) **Route**IV **Schedule of Administration**On days 1, 8, and 15 of a 28‐day cycleDrug 2  **Generic/Working Name**Erlotinib **Drug Class**EGFR **Dose**100 milligrams (mg) **Route**Oral (p.o.) **Schedule of Administration**DailyDrug 3  **Generic/Working Name**Panitumumab **Drug Class**EGFR **Dose**4 milligrams (mg) per kilogram (kg) **Route**IV **Schedule of Administration**On days 1 and 15 of a 28‐day cycle

Patient Characteristics (Control -- Arm A) {#onco12812-sec-0010}
==========================================

Number of Patients, Male29Number of Patients, Female17StageMetastaticAgeMedian (range): 60.5 yearsNumber of Prior Systemic TherapiesMedian (range): 0Performance Status: ECOG0 --- 52.2%1 --- 47.8%2 ---3 ---Unknown ---Cancer Types or Histologic SubtypesAdenocarcinoma, 46

Patient Characteristics (Experimental -- Arm B) {#onco12812-sec-0011}
===============================================

Number of Patients, Male31Number of Patients, Female15StageMetastaticAgeMedian (range): 62 yearsNumber of Prior Systemic TherapiesMedian (range): 0Performance Status: ECOG0 --- 50%1 --- 50%2 ---3 ---Unknown ---Cancer Types or Histologic SubtypesAdenocarcinoma, 46

Primary Assessment Method (Control -- Arm A) {#onco12812-sec-0012}
============================================

TitleGemcitabine/ErlotinibNumber of Patients Enrolled46Number of Patients Evaluable for Toxicity46Number of Patients Evaluated for Efficacy46Evaluation MethodRECIST 1.0Response Assessment -- CR*n* = 0 (0%)Response Assessment -- PR*n* = 5 (10.9%)Response Assessment -- SD*n* = 15 (32.5%)Response Assessment -- PD*n* = 25 (54.3%)Response Assessment -- Other*n* = 1 (2.2%)(Median) Duration Assessments -- PFS2 months; 95% CI, 1.8--3.3 months(Median) Duration Assessments -- OS4.2 months; 95% CI, 3.5--7.8 monthsOutcome NotesOutcomes are summarized in Table [2](#onco12812-tbl-0002){ref-type="table"}.

Primary Assessment Method for Phase II Experimental {#onco12812-sec-0013}
===================================================

TitleGemcitabine/Erlotinib/PanitumumabNumber of Patients Enrolled46Number of Patients Evaluable for Toxicity46Number of Patients Evaluated for Efficacy46Evaluation MethodRECIST 1.0Response Assessment -- PR*n* = 5 (10.9%)Response Assessment -- SD*n* = 24 (52.2%)Response Assessment -- PD*n* = 12 (26.1%)Response Assessment -- Other*n* = 5 (10.9%)(Median) Duration Assessments -- PFS2 months; CI, 1.8--3.3 months(Median) Duration Assessments -- OS4.2 months; CI, 3.5--7.8 monthsOutcome NotesOutcomes are summarized in Table [2](#onco12812-tbl-0002){ref-type="table"}.

Adverse Events {#onco12812-sec-0014}
==============

Adverse events are summarized in Table [3](#onco12812-tbl-0003){ref-type="table"}. 

Assessment, Analysis, and Discussion {#onco12812-sec-0015}
====================================

CompletionStudy completedInvestigator\'s AssessmentLevel of activity did not meet planned endpoint

 {#onco12812-sec-2015}

Pancreatic cancer is a highly lethal malignancy, and the survival of patients with advanced disease is less than a year, ranging from 6 to 11 months in patients on clinical trials. Long‐term survivors are rare, and even among patients with surgically resected disease, the 10‐year overall survival is 3.9% \[[6](#onco12812-bib-0006){ref-type="ref"}\]. Most patients who undergo resection will suffer a recurrence within 5 years, which is invariably fatal. Adjuvant therapy improves outcomes following surgery, but even with such therapy, the outcome is poor and recurrences remain very common \[[7](#onco12812-bib-0007){ref-type="ref"}\], \[[8](#onco12812-bib-0008){ref-type="ref"}\]. Given the high recurrence rate following surgery and the fact that the majority of patients have either metastatic or locally advanced disease at diagnosis, there is a great need for better systemic therapy. Gemcitabine was the standard therapy for advanced pancreatic cancer for more than 10 years, and multiple trials combining cytotoxic or targeted therapy with gemcitabine showed no improvement over gemcitabine alone \[[9](#onco12812-bib-0009){ref-type="ref"}\].

The epidermal growth factor receptor (EGFR) pathway has been considered a potential target for therapy in pancreatic cancer. Increased expression of EGFR and its epidermal growth factor ligand are detected in pancreatic cancer tissues and predict for poor prognosis \[[10](#onco12812-bib-0010){ref-type="ref"}\], \[[11](#onco12812-bib-0011){ref-type="ref"}\]. Blocking the EGFR pathway in preclinical models was shown to suppress pancreatic cancer growth, suggesting a potential therapeutic target \[[12](#onco12812-bib-0012){ref-type="ref"}\], \[[13](#onco12812-bib-0013){ref-type="ref"}\]. Dual EGFR blockage with a monoclonal antibody and a tyrosine kinase inhibitor was also shown to have effect on tumor growth, suggesting utility in patients with pancreatic cancer \[[14](#onco12812-bib-0014){ref-type="ref"}\]. *KRAS* mutations are very common in pancreatic cancer and may be predictive of an inferior survival, but unlike in colorectal cancer, *KRAS* mutations do not appear to predict outcomes in patients with pancreatic cancer treated with EGFR inhibitors \[[15](#onco12812-bib-0015){ref-type="ref"}\], \[[16](#onco12812-bib-0016){ref-type="ref"}\], \[[17](#onco12812-bib-0017){ref-type="ref"}\].

The combination of gemcitabine and erlotinib showed a very modest and statistically significant prolongation of overall survival in patients with metastatic pancreatic cancer, but the clinical significance was questionable, and the combination never gained traction \[[2](#onco12812-bib-0002){ref-type="ref"}\]. It was not until 2011 that substantial improvements were made, when oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) was shown to substantially prolong overall survival compared with gemcitabine alone, from 6.8 months to 11.1 months \[[18](#onco12812-bib-0018){ref-type="ref"}\]. Shortly thereafter, the combination of gemcitabine and albumin‐bound paclitaxel (nab‐paclitaxel) was shown to be superior to gemcitabine alone, prolonging the overall survival of patients from 6.7 months to 8.5 months \[[19](#onco12812-bib-0019){ref-type="ref"}\]. Gemcitabine alone is no longer considered an acceptable therapy for metastatic pancreatic cancer except for patients with impaired performance status or for patients who desire to receive less aggressive, and less toxic, albeit less effective, therapy \[[20](#onco12812-bib-0020){ref-type="ref"}\].

Our trial was designed before FOLFIRINOX and gemcitabine with nab‐paclitaxel were shown to be superior to gemcitabine alone and when there was still a substantial enthusiasm for EGFR‐directed therapy. An early phase II trial of gemcitabine with cetuximab suggested a benefit of the combination indicating that EGFR was a potential target in pancreatic cancer \[[21](#onco12812-bib-0021){ref-type="ref"}\]. A National Cancer Institute of Canada phase III trial of erlotinib given with gemcitabine, an oral EGFR inhibitor, showed a statistically significant but very modest prolongation of overall survival \[[2](#onco12812-bib-0002){ref-type="ref"}\]. These findings, along with preclinical data, led to the design of our trial testing the hypothesis that two EGFR inhibitors of different classes could be superior to gemcitabine and erlotinib, a reasonable therapy standard at that time. Unfortunately, a large phase III trial (Southwest Oncology Group S0205) failed to show improvement of survival in patients treated with gemcitabine and cetuximab over gemcitabine alone \[[3](#onco12812-bib-0003){ref-type="ref"}\]. In this large trial, there was no difference in overall survival of patients among the two arms---6.3 months for the combination versus 5.9 months for gemcitabine alone (hazard ratio, 1.06; 95% confidence interval, 0.91--1.23; *p* = .23)---and a 2‐ week improvement was seen in the time to treatment failure (*p* = .006).

The current trial showed a statistically significant difference observed in terms of overall survival favoring the combination of dual EGFR inhibition and gemcitabine. The dual EGFR inhibition therapy was more toxic, as expected. The relevance of this finding is of uncertain clinical significance, as gemcitabine monotherapy can no longer be considered an appropriate chemotherapy backbone for combination therapy with targeted agents given the superiority of cytotoxic doublet or triplet therapy, and toxicities, especially dermatological, were substantial. Dual EGFR inhibition may be even more challenging in conjunction with chemotherapy doublets or triplets given the adverse events seen with gemcitabine alone. Further studies of EGFR inhibitors administered concurrently with cytotoxic agents are unlikely to result in a meaningful improvement in the outcome of patients with metastatic pancreatic cancer and cannot be recommended.

Figure and Tables {#onco12812-sec-3013}
=================

###### Trial and patient characteristics

![](onco12812-tbl-0001){#nlm-graphic-5}

Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status.

###### Outcomes

![](onco12812-tbl-0002){#nlm-graphic-7}

###### Adverse events, grades 3 and 4

![](onco12812-tbl-0003){#nlm-graphic-9}

Bold *p* values indicate statistical significance.

Abbreviation: ALT, alanine aminotransferase.

![Progression‐free survival by treatment arm.\
Abbreviations: CI, confidence interval; EGFR, epidermal growth factor receptor; Gem, gemcitabine.](onco12812-fig-0002){#onco12812-fig-0002}

The following institutional networks participated in this study: Colorado Cancer Research Program NCORP (National Cancer Institute \[NCI\] Community Oncology Research Program), Denver, CO, Keren Sturtz, UG1CA189805; Dayton NCI Community Oncology Research Program, Dayton, OH, Howard Gross, UG1CA189957; Geisinger Cancer Institute NCI Community Oncology Research Program, Danville, PA, Srilatha Hosur, UG1CA189847; Hawaii Minority Underserved NCORP, Honolulu, HI, Jeffrey Berenberg, UG1CA189804; Iowa‐Wide Oncology Research Coalition NCORP, Des Moines, IA, Robert Behrens, UG1CA189816; Mayo Clinic LAPS, Rochester, MN, Steven Alberts, U10CA180790; Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, MN, Daniel Anderson, UG1CA189863; Michigan Cancer Research Consortium NCORP, Ann Arbor, MI, Philip Stella, UG1CA189971; Missouri Valley Cancer Consortium CCOP (Community Clinical Oncology Program), Omaha, NE, Gamini Soori, U10CA063849; Montana Cancer Consortium NCORP, Billings, MT, Benjamin Marchello, UG1CA189872; Northern Indiana Cancer Research Consortium, South Bend, IN; Michael Method, U10CA086726; Ochsner NCI Community Oncology Research Program, New Orleans, LA, John Cole, UG1CA189870; Pacific Cancer Research Consortium NCORP, Seattle, WA, Alison Conlin, UG1CA189953; Rapid City Regional Hospital, Rapid City, SD, Joshua Lukenbill; Sanford NCI Community Oncology Research Program of the North Central Plains, Sioux Falls, SD, Preston Steen, UG1CA189825; Southeast Clinical Oncology Research Consortium NCORP, Winston‐Salem, NC, James Atkins, UG1CA189858; Toledo Clinic Cancer Centers‐Toledo, Toledo, OH, Rex Mowat; Toledo Community Hospital Oncology Program CCOP, Toledo, OH, Rex Mowat; Wichita NCI Community Oncology Research Program, Wichita, KS, Shaker Dakhil, UG1CA189808; and Wisconsin NCI Community Oncology Research Program, Marshfield, WI, Anthony Jaslowski, UG1CA189956.
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